AMICUS THERAPEUTICS RAISES $55 MILLION SERIES C FINANCING

Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced the closing of a $55 million Series C financing. The company intends to use the proceeds to advance its drug pipeline based on the company's unique technology that has the potential to transform the treatment of human genetic diseases. Amicus' lead compound Amigal(TM) (migalastat hydrochloride) is in a Phase II clinical program for Fabry disease.
Yahoo News